VEA
STOK icon

Virtus ETF Advisers’s Stoke Therapeutics STOK Stock Holding History

Virtus ETF Advisers’s Portfolio STOK Stock Details STOK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-5,770
Closed -$63.6K – 754
2024
Q4 		$63.6K Buy
5,770
+514
+10% +$6.32K 0.03% 430
2024
Q3 		$64.6K Buy
5,256
+89
+2% +$1.26K 0.03% 435
2024
Q2 		$69.8K Buy
+5,167
New +$69.8K 0.03% 430
2023
Q4 		– Sell
-7,893
Closed -$31.1K – 459
2023
Q3 		$31.1K Sell
7,893
-785
-9% -$5.16K 0.02% 427
2023
Q2 		$92.2K Sell
8,678
-3,400
-28% -$36.2K 0.05% 412
2023
Q1 		$101K Sell
12,078
-4,637
-28% -$41.8K 0.06% 337
2022
Q4 		$154K Buy
16,715
+6,745
+68% +$70.1K 0.08% 339
2022
Q3 		$128K Buy
9,970
+75
+0.8% +$1.2K 0.05% 383
2022
Q2 		$131K Buy
9,895
+1,336
+16% +$20.3K 0.05% 349
2022
Q1 		$180K Sell
8,559
-511
-6% -$10.2K 0.08% 206
2021
Q4 		$218K Buy
9,070
+3,568
+65% +$85.1K 0.08% 196
2021
Q3 		$140K Sell
5,502
-284
-5% -$7.92K 0.06% 353
2021
Q2 		$195K Buy
5,786
+425
+8% +$15K 0.08% 359
2021
Q1 		$208K Buy
5,361
+97
+2% +$5.52K 0.09% 323
2020
Q4 		$326K Buy
+5,264
New +$241K 0.14% 188

Other funds holding STOK

ST
Skorpios Trust Limassol, Cyprus $53.2M AUM 90.96% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
LCM
Lynx1 Capital Management San Juan, Puerto Rico $633M AUM 173.22% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Toronto Dominion Bank
Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $69.7B AUM 40.86% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Virtus ETF Advisers's STOK Position: Q1 2025 in Review

Virtus ETF Advisers sold out of Stoke Therapeutics (STOK) in Q1 2025, closing a stake of 5,770 shares — an estimated $63.6K sold.

Virtus ETF Advisers first reported a position in STOK in Q4 2020 and held it in 15 quarters. The position peaked at $326K in Q4 2020. 126 funds tracked by Wall St. Rank hold STOK as of Q1 2025.

  • Virtus ETF Advisers reported no remaining Stoke Therapeutics position as of Q1 2025 after selling out during the quarter.
  • Virtus ETF Advisers sold 5,770 Stoke Therapeutics shares in Q1 2025, an estimated $63.6K.
  • Virtus ETF Advisers first reported a position in Stoke Therapeutics in Q4 2020 and held it in 15 quarters.
  • Virtus ETF Advisers's Stoke Therapeutics position peaked at $326K in Q4 2020.
  • 126 funds tracked by Wall St. Rank held Stoke Therapeutics as of Q1 2025.

Based on Virtus ETF Advisers's 13F filing for Q1 2025, filed 14 May 2025.